Opdivo nivolumab: Additional Phase III data

Additional data from the open-label, international Phase III CheckMate -141 trial in 361 patients with SCCHN showed that 3 mg/kg IV Opdivo every 2 weeks led to a median OS, the primary endpoint, of 7.5 months vs. 5.1 months for investigator’s

Read the full 417 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE